Fig. 1: Prior exposure to endemic alpha and beta-coronaviruses among healthy adult volunteers.

Distribution of A human endemic coronavirus log 10 transformed binding antibody multiplex assay (BAMA) response magnitudes in baseline samples (D01) among VAT00001 trial participants, B fold-rise in neutralization titer and SARS-CoV-2 binding antibody concentration at D36 from baseline, stratified by age stratum and dosing schedule. Treatment assignments are shown for both panels, and C principal components analysis (PCA) plot of human endemic coronavirus response magnitude and treatment assignment. Ab antibody, D01 day 1, D36 day 36, HCoV human coronavirus, MFI mean fluorescence intensity, PC principal component, RBD receptor binding domain.